| Novartis–Dyno Therapeutics: gene therapy, 202005– collab design of AVV vectors for ophthalmic gene therapies using AI-based CapsidMap platform |
2020-05-11 |
| Pluristem–Dentons: legal services, 202005 supply service Dentons is adivsor with regard to €50m EIB loan financing |
2020-05-05 |
| ADC Therapeutics–Deerfield: credit, 202005– convertible credit facility $115m in two conditionable disbursements of $65m + $50m |
2020-05-01 |
| Moderna–Lonza: biologicals contract manufacturing, 202005–203004 collab strategic 10y manufacture of mRNA1273 vaccine + other Moderna products |
2020-05-01 |
| Pfizer–Valneva: Lyme disese vaccine, 202004– collab developm of VLA15 + commerc by Pfizer $130m upfront + $178m milestones + 2-digit tiered royalties |
2020-04-30 |
| Kurma–EU (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor EIF |
2020-04-29 |
| Kurma–Institut Pasteur: investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor Pasteur Institute |
2020-04-29 |
| Kurma–North Rhine-Westphalia (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor NRW.BANK |
2020-04-29 |
| Kurma–SEVERAL: investment, 202004 final closing of Kurma Biofund III with €160m |
2020-04-29 |
| Genedata–Cergentis: genomic software tools, –202004 collab developm of Genedata Selector s/w for automating TLA data analysis workflow |
2020-04-28 |
| Gustave Roussy–Biognosys: MS-based proteomics, 202004– collab using proteomic profiling in attempt to repurpose tocilizumab for Covid-19 |
2020-04-28 |
| Compass Pathways–Atai Life Sciences: investment, 202004 financing round Series B totalling $80m incl existing investor Atai Life Sciences |
2020-04-27 |
| Compass Pathways–SEVERAL: investment, 202004 financing round Series B $80m from existing + new investors |
2020-04-27 |
| Heidelberg Pharma–Hopp Group: investment, 202004 private placement totalling €14.4m incl €13.7m from main investor Dievini Hopp |
2020-04-27 |
| Heidelberg Pharma–OTHER: investment, 202004 private placement totalling €14.4m incl €719k to institutional investors |
2020-04-27 |
| Heidelberg Pharma–SEVERAL: investment, 202004 private placement €14.4m with 2.82m new shares at €5.1/share incl €13.7m from Dievini Hopp |
2020-04-27 |
| ADC Therapeutics–SEVERAL: investment, 202004–202005 IPO at NYSE $267.6m with 14.1m shares at $19/share |
2020-04-24 |
| Pluristem–EU (govt): credit, 202004– EIB financing up to €50m in three milestone-dependent tranches |
2020-04-24 |
| Biotecon–EW Group: investment, 202004 acquisition of Biotecon Diagnostics GmbH by BioChek BV |
2020-04-23 |
| FoRx Therapeutics–Life Sciences Partners: investment, 202004 seed financing round totalling €10m incl co-investor LSP |
2020-04-22 |
| FoRx Therapeutics–Merck (DE): investment, 202004 seed financing round totalling €10m incl co-lead investor M Ventures |
2020-04-22 |
| FoRx Therapeutics–Novartis: investment, 202004 seed financing round totalling €10m incl co-lead investor Novartis Venture Fund |
2020-04-22 |
| FoRx Therapeutics–Omega Funds: investment, 202004 seed financing round totalling €10m incl co-lead investor Omega Funds |
2020-04-22 |
| FoRx Therapeutics–Optimum Strategic Communications: public relations, 202004 service existent by Optimum |
2020-04-22 |
| FoRx Therapeutics–Pfizer: investment, 202004 seed financing round totalling €10m incl co-investor Pfizer Ventures |
2020-04-22 |
| FoRx Therapeutics–SEVERAL: investment, 202004 seed financing round €10m co-led by M Ventures + Novartis Venture Fund + Omega Funds |
2020-04-22 |
| Valneva–Dynavax: SARS-CoV-2 vaccine, 202004– collab development combining Valneva’s vaccine technology with adjuvant CpG 1018 of Dynavax |
2020-04-22 |
| Centogene–Ubirch: blockchain technology, 202004 collab announcing secure blockchain solution for storing SARS-CoV-2 test results |
2020-04-17 |
| Evotec–Leon-Nanodrugs: nanoparticle technology, 202004– collab €na strategic partnership incl equity investment |
2020-04-16 |
| Evox Therapeutics–Cevec: cell line technology, 202004– license €na for use of CAP technology to produce exosome therapeutics as part of ongoing collab |
2020-04-16 |
| Leon-Nanodrugs–Albany Private Equity: investment, 202004 financing round Series B incl existing + co-investor Albany Private Equity Holidngs Pty Ltd |
2020-04-16 |
| Leon-Nanodrugs–Bavaria (govt): investment, 202004 financing round Series B incl new + co-investor BayBG |
2020-04-16 |
| Leon-Nanodrugs–CD-Venture: investment, 202004 financing round Series B incl existing + co-investor CD-Venture GmbH |
2020-04-16 |
| Leon-Nanodrugs–Eckenstein-Geigy-Stiftung: investment, 202004 financing round Series B incl existing + co-investor Eckenstein-Geigy-Stiftung |
2020-04-16 |
| Leon-Nanodrugs–Evotec: investment, 202004 financing round Series B incl new + lead investor Evotec |
2020-04-16 |
| Leon-Nanodrugs–LOF Leon Partnership: investment, 202004 financing round Series B incl existing + co-investor LOF Leon Partnership LP |
2020-04-16 |
| Leon-Nanodrugs–SEVERAL: investment, 202004 financing round Series B led by new investor Evotec |
2020-04-16 |
| Leon-Nanodrugs–TVM: investment, 202004 financing round Series B incl existing + co-investor TVM Life Science Innovation I LP |
2020-04-16 |
| Centogene–FTI Consulting: public relations, 202004 service existent by FTI Consulting |
2020-04-15 |
| MOMA Therapeutics–Nextech: investment, 202004 financing round Series A totalling $86m incl co-investor Nextech Invest |
2020-04-15 |
| MOMA Therapeutics–SEVERAL: investment, 202004 financing round Series A $86m led by Third Rock Ventures |
2020-04-15 |
| Boehringer–Insilico Medicine: drug target discovery, 202004– collab research using machine learning + Pandomics Discovery Platform |
2020-04-14 |
| Roche–Arrakis Therapeutics: RNA-targeting drugs, 202004– collab strategic + license $190m upfront discovery of RNA-targeting small molecule drugs |
2020-04-08 |
| Takeda–Evotec: drug discovery services, 202004– collab multi-year €na gene therapy research alliance |
2020-04-06 |
| Evotec–PanCella: iPSC technology, 202004– license €na for use of iACT Stealth Cells + FailSafe technology with EVOcells platform |
2020-04-02 |
| PanCella–Evotec: investment, 202004 minority equity investment €na by Evotec in connection with license agreement |
2020-04-02 |
| Rgenta Therapeutics–Boehringer: investment, 202004 seed financing round totalling $20m incl co-lead investor BIVF |
2020-04-02 |
| Rgenta Therapeutics–SEVERAL: investment, 202004 seed financing round $20m co-led by BIVF + Matrix Partners China |
2020-04-02 |
| iTeos Therapeutics–SEVERAL: investment, 202004 financing round Series B2 $125m co-led by RA Capital Management + Boxer Capital |
2020-04-01 |
| Vaderis Therapeutics–Almac: allosteric AKT inhibitors, 202004 acquisition portfolio of allosteric AKT inhibitors from Almac Discovery Ltd by Vedaris |
2020-04-01 |
| Affinia Therapeutics–Lonza: AAV technology, 202003 license existent from Lonza + Massachusetts Eye and Ear |
2020-03-31 |
| Affinia Therapeutics–Lonza: investment, 202003 financing round Series A totalling $60m incl existing + co-investor Lonza |
2020-03-31 |
| Affinia Therapeutics–SEVERAL: investment, 202003 financing round Series A $60m co-led by Atlas Venture + F-Prime Capital + NEA |
2020-03-31 |
| Gilde Investment–Germany (govt): investment, 202003 first + final close of Gilde Healthcare V fund totalling €416m incl investor KfW Capital |
2020-03-31 |
| Gilde Investment–Haniel: investment, 202003 first + final close of Gilde Healthcare V fund totalling €416m incl investor Haniel |
2020-03-31 |
| Gilde Investment–SEVERAL: investment, 202003 first + final close of €416m Gilde Healthcare V fund incl investors Philips + Rabo Corp Investments |
2020-03-31 |
| Obi Medical–Roche: investment, 202003 acquisition of Obi Medical ApS by Roche |
2020-03-31 |
| Provirex–Hamburg (govt): investment, 202003 seed financing from Ascenion + Innovationsstarter Fonds Hamburg |
2020-03-31 |
| Provirex–Life Science-Stiftung: investment, 202003 seed financing from Ascenion + Innovationsstarter Fonds Hamburg |
2020-03-31 |
| SutroVax–Roche: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Roche Venture Fund |
2020-03-26 |
| SutroVax–SEVERAL: investment, 202003 financing round Series D $110m co-led by new investors RA Capital + Janus Henderson |
2020-03-26 |
| Debiopharm–3B Pharmaceuticals: radiopharmaceutical, 202003– collab research + license ww excl for radioligand programme targeting CAIX enzyme |
2020-03-25 |
| Roche–Forge Therapeutics: antibiotics, 202003– collab research + license option up to $190.5m for FG-LpxC LUNG program for lung infections |
2020-03-25 |
| Immunogenesis–Minapharm: biopharma production, 202003– supply €na cell line + process developm + production of I-O-candidate by ProBiogen AG |
2020-03-24 |
| Bayer–Curadev: STING agonists, 202003– collab research + license agreem incl upfront payment + €250m milestones + single-digit royalties |
2020-03-23 |
| DeepSee project–Germany (govt): grant, 202003– funding from BMWi (ZIM) + Enterprise Singapore for single cell analysis for cancer drug RnD |
2020-03-23 |
| DeepSee project–Proteona: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug RnD |
2020-03-23 |
| DeepSee project–Singapore (govt): grant, 202003– funding from Enterprise Singapore + German BMWi for single cell analysis for cancer drug RnD |
2020-03-23 |
| DeepSee project–Synovo: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug RnD |
2020-03-23 |
| DeepSee project–Univ Tübingen: single cell analysis, 202003– collab NMI project partner AI-driven multi-omics single cell analysis for cancer drug RnD |
2020-03-23 |
| Koki Holdings–Eppendorf: investment, 202003– acquisition €na of Koki’s Centrifuge + Processing business by Eppendorf from KKR |
2020-03-19 |
| BMS–Oxford BioMedica: lentiviral vector technology, 202003– license non-excl + supply agreem LentiVector for CAR-T + TCR-T therapeutics of Juno |
2020-03-18 |
| OncoOne–Austria (govt): investment, 202003 financing round Series A totalling €13m incl investor AWS Austria Wirtschaftsservice |
2020-03-18 |
| OncoOne–Austria (govt): investment, 202003 financing round Series A totalling €13m incl investor FFG Austrian Research Promotion Agency |
2020-03-18 |
| OncoOne–OTHER: investment, 202003 financing round Series A totalling €13m incl two family offices as investors |
2020-03-18 |
| OncoOne–SEVERAL: investment, 202003 financing round Series A €13m investors include FFG + AWS + two family offices |
2020-03-18 |
| OncoOne–Trophic Communications: public relations, 202003 service existent by Trophic Communications |
2020-03-18 |
| BioNTech–Pfizer: investment, 202003 equitiy investment $113m by Pfizer in connection with COVID-19 vaccine collaboration |
2020-03-17 |
| Immatics–Arya Sciences: investment, 202003 reverse merger resulting in Nasdaq-listing of Immatics + $148m cash held by Arya |
2020-03-17 |
| Immatics–SEVERAL: investment, 202003 common stock PIPE $104m led by Perceptive Advisors |
2020-03-17 |
| Pfizer–BioNTech: mRNA-based vaccines, 202003– collab $72m upfront + $563m milestones developm COVID-19 vaccine |
2020-03-17 |
| BioNTech–Fosun: investment, 202003 equity investment €44m for 1.58m ordinary shares by Fosun Pharma as part of COVID-19 vaccine collab |
2020-03-16 |
| Fosun–BioNTech: mRNA-based vaccines, 202003– collab up to €120m + profit sharing development of COVID-19 vaccine in China with Fosun Pharma |
2020-03-16 |
| NanoSyrinx–BioCity (GB): investment, 202003–202009 pre-seed financing round incl co-investor BioCity Group |
2020-03-16 |
| NanoSyrinx–Merck (DE): investment, 202003–202009 pre-seed financing round incl lead investor M Ventures |
2020-03-16 |
| NanoSyrinx–Midven: investment, 202003–202009 pre-seed financing round incl co-investor UKI2S Fund |
2020-03-16 |
| NanoSyrinx–SEVERAL: investment, 202003–202009 pre-seed financing round led by M Ventures + incl BioCity + UKI2S Fund |
2020-03-16 |
| Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS |
2020-03-10 |
| Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF |
2020-03-10 |
| Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical |
2020-03-10 |
| Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF |
2020-03-10 |
| Roche–Genedata: bioinformatics, 202003– supply Chugai Pharmaceutical implements Genedata Profiler for biomarker discovery + validation |
2020-03-10 |
| iAtros–Bavaria (govt): investment, 202003 seed financing round totalling €2m incl investor Bayern Kapital |
2020-03-09 |
| iAtros–High-Tech Gründerfonds: investment, 202003 seed financing round totalling €2m incl investor HTGF |
2020-03-09 |
| iAtros–OTHER: investment, 202003 seed financing round totalling €2m incl several business angels |
2020-03-09 |
| iAtros–SEVERAL: investment, 202003 seed financing round €2m from HTGF + Bayern Kapital + several business angels |
2020-03-09 |
| Numab–MacDougall Biomedical Communications: public relations, 202003 service existent by MacDougall |
2020-03-09 |
| Ubirch–SEVERAL: investment, 202003 third financing round seven-digit € amount led by hubraum Deutsche Telekom + NRW.BANK |
2020-03-06 |
| Qiagen–Barclays: financial services, 202003 supply service Barclays Bank plc is financial advisor w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–De Brauw Blackstone Westbroek: legal services, 202003 supply service De Brauw BW NV is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 15 16 17 ... 48 49 50 
Date![Picture [iito] No Content Marketing 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-content-marketing.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
